| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000008375 |
| Receipt No. | R000009845 |
| Official scientific title of the study | Third regimen for eradication of Helicobacter pylori resistant against first and sdcond regimen |
| Date of disclosure of the study information | 2012/07/09 |
| Last modified on | 2016/06/15 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Third regimen for eradication of Helicobacter pylori resistant against first and sdcond regimen | |
| Title of the study (Brief title) | Third regimen for eradication of Helicobacter pylori | |
| Region |
|
|
| Condition | ||||
| Condition | Helicobacter pylori infection | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | Third regimen for eradication of Helicobacter pylori resistant against first and second regimen |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | success for eradication of Helicobacter pylori |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Patients receive the regimen shown below.
rabeprazole sodium 10 mg X 3 times/day+amoxicillin 500 mg X 3 times/day+ levofloxacin 500 mg once a day for 14 days. |
|
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | a person who had first and second regimen for eradication of Helicobacter pylori and failed to eradicate Helicobacter pylori | |||
| Key exclusion criteria | The subjects who has allergic hypersensitivity against the drugs used in this study.
The subjects who are judged to be inappropriate for this study by doctors conducting the study. |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Tetsuya tanigawa |
| Organization | Osaka City University Graduate School of Medicine |
| Division name | Department of Gastroenterology |
| Address | 1-4-3 Asahimachi, Abeno-ku Osaka City, Osaka 545-8585, Japan |
| TEL | |
| Public contact | |
| Name of contact person | |
| Organization | Osaka City University Graduate School of Medicine |
| Division name | Department of Gastroenterology |
| Address | |
| TEL | |
| Homepage URL | |
| Sponsor | |
| Institute | Osaka City University Graduate School of Medicine |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Osaka City University Graduate School of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000009845 |